It is unknown whether human papillomavirus (HPV) status impacts the prognosis of early stage cervical glandular lesions. This study assessed the recurrence and survival rates of in situ/microinvasive adenocarcinomas (AC) according to HPV status during a 5-year follow-up. The data were retrospectively analyzed in women with available HPV testing before treatment. One hundred and forty-eight consecutive women were analyzed. The number of HPV-negative cases was 24 (16.2%). The survival rate was 100% in all participants. The recurrence rate was 7.4% (11 cases, including four invasive lesions (2.7%)). Cox proportional hazards regression showed no difference in recurrence rate between HPV-positive and HPV-negative cases (p = 0.148). HPV genotyping, available for 76 women and including 9/11 recurrences, showed a higher relapse rate for HPV-18 than HPV-45 and HPV-16 (28.5%, 16.6%, and 9.52%, p = 0.046). In addition, 60% and 75% of in situ and invasive recurrences, respectively, were HPV-18 related. The present study showed that most ACs were positive for high-risk HPV, and the recurrence rate was unaffected by HPV status. More extensive studies could help evaluate whether HPV genotyping may be considered for recurrence risk stratification in HPV-positive cases.

Giannella, L., Delli Carpini, G., Di Giuseppe, J., Bogani, G., Sopracordevole, F., Clemente, N., Giorda, G., De Vincenzo, R. P., Evangelista, M. T., Gardella, B., Dominoni, M., Monti, E., Alessi, C., Alessandrini, L., Pagan, A., Caretto, M., Ghelardi, A., Amadori, A., Origoni, M., Barbero, M., Raspagliesi, F., Simoncini, T., Vercellini, P., Scambia, G., Ciavattini, A., In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group), <<CANCERS>>, 2023; 15 (11): 1-12. [doi:10.3390/cancers15112876] [https://hdl.handle.net/10807/281296]

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group)

De Vincenzo, Rosa Pasqualina
Membro del Collaboration Group
;
Scambia, Giovanni
Supervision
;
2023

Abstract

It is unknown whether human papillomavirus (HPV) status impacts the prognosis of early stage cervical glandular lesions. This study assessed the recurrence and survival rates of in situ/microinvasive adenocarcinomas (AC) according to HPV status during a 5-year follow-up. The data were retrospectively analyzed in women with available HPV testing before treatment. One hundred and forty-eight consecutive women were analyzed. The number of HPV-negative cases was 24 (16.2%). The survival rate was 100% in all participants. The recurrence rate was 7.4% (11 cases, including four invasive lesions (2.7%)). Cox proportional hazards regression showed no difference in recurrence rate between HPV-positive and HPV-negative cases (p = 0.148). HPV genotyping, available for 76 women and including 9/11 recurrences, showed a higher relapse rate for HPV-18 than HPV-45 and HPV-16 (28.5%, 16.6%, and 9.52%, p = 0.046). In addition, 60% and 75% of in situ and invasive recurrences, respectively, were HPV-18 related. The present study showed that most ACs were positive for high-risk HPV, and the recurrence rate was unaffected by HPV status. More extensive studies could help evaluate whether HPV genotyping may be considered for recurrence risk stratification in HPV-positive cases.
2023
Inglese
Giannella, L., Delli Carpini, G., Di Giuseppe, J., Bogani, G., Sopracordevole, F., Clemente, N., Giorda, G., De Vincenzo, R. P., Evangelista, M. T., Gardella, B., Dominoni, M., Monti, E., Alessi, C., Alessandrini, L., Pagan, A., Caretto, M., Ghelardi, A., Amadori, A., Origoni, M., Barbero, M., Raspagliesi, F., Simoncini, T., Vercellini, P., Scambia, G., Ciavattini, A., In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-Up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group), <<CANCERS>>, 2023; 15 (11): 1-12. [doi:10.3390/cancers15112876] [https://hdl.handle.net/10807/281296]
File in questo prodotto:
File Dimensione Formato  
cancers-15-02876 (3).pdf

accesso aperto

Licenza: Creative commons
Dimensione 975.92 kB
Formato Adobe PDF
975.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/281296
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact